Stemedica Signs License Agreement with Pulthera, LLC for All Respiratory Indications Including Those Related to COVID-19

Stemedica Cell Technologies, Inc. announced that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its MSC technologies in the treatment of COVID-19 and additional pulmonary conditions.